Neuropathy management strategies in patients receiving BV + AVD
| Treatment modification . | Overall (n = 153), n (%) . |
|---|---|
| BV modification | 67 (44%) |
| Dose reduction | 26 (17%) |
| Discontinuation | 19 (12%) |
| Dose reduction followed by discontinuation | 16 (11%) |
| Dose hold followed by dose reduction | 6 (4%) |
| Vinblastine modification | 26 (17%) |
| Hold or discontinuation | 16 (10%) |
| Dose reduction | 10 (7%) |
| BV continued | 9 (6%) |
| Treatment modification . | Overall (n = 153), n (%) . |
|---|---|
| BV modification | 67 (44%) |
| Dose reduction | 26 (17%) |
| Discontinuation | 19 (12%) |
| Dose reduction followed by discontinuation | 16 (11%) |
| Dose hold followed by dose reduction | 6 (4%) |
| Vinblastine modification | 26 (17%) |
| Hold or discontinuation | 16 (10%) |
| Dose reduction | 10 (7%) |
| BV continued | 9 (6%) |
Because BV modification was our primary interest, more granular data were collected about discontinuation and dose reduction and the temporal relationship between these events than for vinblastine.